Raquel López-Rodríguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raquel López-Rodríguez has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Veleiro Pérez
Allergy Department, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
2 shared publications - Fernando Pineda
Inmunotek SL Laboratories, 28805 Madrid, Spain
2 shared publications Manuel Jorge Rial
Allergology Section, A Coruña University Hospital Complex, Spain
2 shared publications- Olinda Pérez-Quintero
Allergy Department, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
2 shared publications - Ana Elena Fernández
Inmunotek, S.L., 28805 Alcalá de Henares, Spain
1 shared publication - Ana Martínez-Cañavate
Hospital Universitario Virgen de las Nieves Granada Spain
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (9) , e70472
Exposome‐driven molecular sensitization signatures in pediatric rhinitis and asthma across Spanish regions
Background: Allergic rhinitis and asthma in childhood arise from dynamic interactions between genetic predisposition and the exposome. However, how environmental heterogeneity shapes molecular IgE sensitization profiles during early life remains insufficiently characterized. Methods: We conducted a prospective, observational, multicentre, cross‐sectional study including 354 children (0–15 years) with allergic rhinitis and/or asthma recruited across eight Spanish cities contrasting regional climatic contexts. All patients were skin prick test‐positive to at least one aeroallergen and underwent multiplex component‐resolved diagnostics using the ALEX platform. Sensitization patterns were analyzed, and unsupervised approaches were applied to identify molecular signatures. Results: Molecular IgE profiling revealed a structured sensitization landscape, with 97.5% of children exhibiting reactivity to at least one allergen. A dominant mite‐related pattern and partially distinct pollen‐ and epithelial‐related patterns were observed. PCA identified composite molecular sensitization gradients and descriptive differences in participant distributions across recruitment centres, although substantial overlap was observed between centres. Age‐stratified analyses identified a non‐linear trajectory of sensitization, characterized by early molecular priming in high‐exposure environments, followed by a marked expansion of IgE levels and allergen sensitization during school age. Rhinitis severity was strongly associated with a denser mite sensitization network. In contrast, asthma severity was driven not by mite sensitization alone but by a complex pollen‐related polysensitization. Conclusion: Pediatric IgE sensitization is structured into molecular patterns associated with geography and age, consistent with a role for environmental context in early allergic trajectories. image
- 16 September 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (9) , e70472
Open AccessExposome‐driven molecular sensitization signatures in pediatric rhinitis and asthma across Spanish regions
Background: Allergic rhinitis and asthma in childhood arise from dynamic interactions between genetic predisposition and the exposome. However, how environmental heterogeneity shapes molecular IgE sensitization profiles during early life remains insufficiently characterized. Methods: We conducted a prospective, observational, multicentre, cross‐sectional study including 354 children (0–15 years) with allergic rhinitis and/or asthma recruited across eight Spanish cities contrasting regional climatic contexts. All patients were skin prick test‐positive to at least one aeroallergen and underwent multiplex component‐resolved diagnostics using the ALEX platform. Sensitization patterns were analyzed, and unsupervised approaches were applied to identify molecular signatures. Results: Molecular IgE profiling revealed a structured sensitization landscape, with 97.5% of children exhibiting reactivity to at least one allergen. A dominant mite‐related pattern and partially distinct pollen‐ and epithelial‐related patterns were observed. PCA identified composite molecular sensitization gradients and descriptive differences in participant distributions across recruitment centres, although substantial overlap was observed between centres. Age‐stratified analyses identified a non‐linear trajectory of sensitization, characterized by early molecular priming in high‐exposure environments, followed by a marked expansion of IgE levels and allergen sensitization during school age. Rhinitis severity was strongly associated with a denser mite sensitization network. In contrast, asthma severity was driven not by mite sensitization alone but by a complex pollen‐related polysensitization. Conclusion: Pediatric IgE sensitization is structured into molecular patterns associated with geography and age, consistent with a role for environmental context in early allergic trajectories. image
- Open Access
- 1 September 2022
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 50 (5) , 16-22
Quality of life against seasonal vs perennial allergens: ESPRINT-15 modified in the pediatric population
Introduction: Allergic rhinitis (AR) is a clinical syndrome characterized by IgE-mediated inflammation of the nasal mucosa. The present study investigates the quality of life (QoL) with AR among adults, using widely validated questionnaires, unlike in pediatric patients. Materials and methods: A cross-sectional descriptive observational study was conducted, analyzing the QoL of 102 children with AR aged between 10-15 years, belonging to two health centers (HC) in Zaragoza and two HC in Coruña. The comparison of means between the two groups is carried out using the Student's test or the Mann-Whitney test, considering a value of p˂0.05 to be significant. Results: Around 102 children were studied, with a majority (59.8%) being male and a mean age of 12 years. Around 76.5% have a family history of atopy. It was found that AR is more prevalent in Zaragoza (p ˂0.005), and asthmais highly prevalent in Coruña (p ˂0.001). The most important sensitizations are pollen in Zaragoza (p ˂0.05) and dust mites in A Coruña (p ˂0.001). More treatment needs and associated comorbidities (p˂0.05) were observed in A Coruña. The results of the ESPRINT-15 show that 63% of the patients have a good QoL, 27% fair, and 8.8%, poor. Those sensitized to mites have a worse score (p = 0.02). It was found that 52% of children experienced improvement during home confinement, with no notable differences between the two populations. The use of the mask favored QoL in patients from Zaragoza (p ˂0.001). Conclusion: It was concluded that AR influences the QoL in pediatric patients. Greater QoL involvement, need for treatment, and comorbidities are observed in patients sensitized to dust mites compared to those sensitized to pollens. It was also observed that masks improved the symptoms, stopping patients being sensitized to pollens.
- 1 September 2022
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 50 (5) , 16-22
Open AccessQuality of life against seasonal vs perennial allergens: ESPRINT-15 modified in the pediatric population
Introduction: Allergic rhinitis (AR) is a clinical syndrome characterized by IgE-mediated inflammation of the nasal mucosa. The present study investigates the quality of life (QoL) with AR among adults, using widely validated questionnaires, unlike in pediatric patients. Materials and methods: A cross-sectional descriptive observational study was conducted, analyzing the QoL of 102 children with AR aged between 10-15 years, belonging to two health centers (HC) in Zaragoza and two HC in Coruña. The comparison of means between the two groups is carried out using the Student's test or the Mann-Whitney test, considering a value of p˂0.05 to be significant. Results: Around 102 children were studied, with a majority (59.8%) being male and a mean age of 12 years. Around 76.5% have a family history of atopy. It was found that AR is more prevalent in Zaragoza (p ˂0.005), and asthmais highly prevalent in Coruña (p ˂0.001). The most important sensitizations are pollen in Zaragoza (p ˂0.05) and dust mites in A Coruña (p ˂0.001). More treatment needs and associated comorbidities (p˂0.05) were observed in A Coruña. The results of the ESPRINT-15 show that 63% of the patients have a good QoL, 27% fair, and 8.8%, poor. Those sensitized to mites have a worse score (p = 0.02). It was found that 52% of children experienced improvement during home confinement, with no notable differences between the two populations. The use of the mask favored QoL in patients from Zaragoza (p ˂0.001). Conclusion: It was concluded that AR influences the QoL in pediatric patients. Greater QoL involvement, need for treatment, and comorbidities are observed in patients sensitized to dust mites compared to those sensitized to pollens. It was also observed that masks improved the symptoms, stopping patients being sensitized to pollens.
- 24 May 2022
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 183 (10) , 1089-1094
Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab
Background: Delayed pressure urticaria (DPU) is a rare form of chronic inducible urticaria (CIndU) when it manifests alone. Treatment of DPU is disappointing owing to the lack of response to antihistamines, even when up-dosing. In addition, the absence of randomized clinical trials and the low number of patients included in the studies mean that there is little scientific evidence for the validity of omalizumab in DPU. Objective: Objectives of the study were to perform a real-world study of the effectiveness and safety of omalizumab in DPU patients without chronic spontaneous urticaria or other forms of CIndU and to describe their clinical and diagnostic features. Method: We performed an ambispective observational study of 14 patients with DPU who did not respond to 2 or more second-generation H1-antihistamines in an up-dosing regimen and/or corticosteroids, montelukast, or cyclosporine. Treatment was initiated with omalizumab 300 mg every 4 weeks. We recorded the following: age, time to diagnosis, previous treatment, diagnostic testing (mean time threshold after removing the stimulus and duration of the lesions), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D dimer, total IgE, antithyroid peroxidase (anti-TPO) antibodies, and the Urticaria Control Test (UCT) score before and after the first dose. We evaluated the efficacy of omalizumab according to the Urticaria Control Test score. We analyzed the time to complete or satisfactory response after the first dose (superfast) and its adverse effects. Results: Women accounted for 64.28% patients. The mean age at diagnosis was 43.64 (±13.78) years. The time to diagnosis was 4.53 (±5.54) years. The mean time threshold after removing the stimulus was 4.18 h (±2.75). The mean duration of lesions after testing was 32.42 (±13.8) hours. High ERS values (>20.0 mm/h) were detected in 50% of patients. CRP was >0.5 mg/dL in 42.85% and D dimer levels were high (>500.0 ng/mL) in 3/10 patients. Anti-TPO level was normal in 100% of patients. Total IgE was >100 IU/mL in 6/8 patients. Medium UCT levels before treatment with omalizumab were 3.07 (±2.40), reaching 15.28/16 (±1.72) after the first dose of omalizumab. All 14 patients responded superfast, and none experienced an adverse reaction. Conclusions: Despite the limitation of a low sample size in this real-life study, our findings suggest that omalizumab is a rapid, effective, and safe treatment for patients with DPU refractory to antihistamines in an up-dosing regimen. We recommend omalizumab for patients who do not respond to up-dosing antihistamines and montelukast.
- 24 May 2022
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 183 (10) , 1089-1094
Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab
Background: Delayed pressure urticaria (DPU) is a rare form of chronic inducible urticaria (CIndU) when it manifests alone. Treatment of DPU is disappointing owing to the lack of response to antihistamines, even when up-dosing. In addition, the absence of randomized clinical trials and the low number of patients included in the studies mean that there is little scientific evidence for the validity of omalizumab in DPU. Objective: Objectives of the study were to perform a real-world study of the effectiveness and safety of omalizumab in DPU patients without chronic spontaneous urticaria or other forms of CIndU and to describe their clinical and diagnostic features. Method: We performed an ambispective observational study of 14 patients with DPU who did not respond to 2 or more second-generation H1-antihistamines in an up-dosing regimen and/or corticosteroids, montelukast, or cyclosporine. Treatment was initiated with omalizumab 300 mg every 4 weeks. We recorded the following: age, time to diagnosis, previous treatment, diagnostic testing (mean time threshold after removing the stimulus and duration of the lesions), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D dimer, total IgE, antithyroid peroxidase (anti-TPO) antibodies, and the Urticaria Control Test (UCT) score before and after the first dose. We evaluated the efficacy of omalizumab according to the Urticaria Control Test score. We analyzed the time to complete or satisfactory response after the first dose (superfast) and its adverse effects. Results: Women accounted for 64.28% patients. The mean age at diagnosis was 43.64 (±13.78) years. The time to diagnosis was 4.53 (±5.54) years. The mean time threshold after removing the stimulus was 4.18 h (±2.75). The mean duration of lesions after testing was 32.42 (±13.8) hours. High ERS values (>20.0 mm/h) were detected in 50% of patients. CRP was >0.5 mg/dL in 42.85% and D dimer levels were high (>500.0 ng/mL) in 3/10 patients. Anti-TPO level was normal in 100% of patients. Total IgE was >100 IU/mL in 6/8 patients. Medium UCT levels before treatment with omalizumab were 3.07 (±2.40), reaching 15.28/16 (±1.72) after the first dose of omalizumab. All 14 patients responded superfast, and none experienced an adverse reaction. Conclusions: Despite the limitation of a low sample size in this real-life study, our findings suggest that omalizumab is a rapid, effective, and safe treatment for patients with DPU refractory to antihistamines in an up-dosing regimen. We recommend omalizumab for patients who do not respond to up-dosing antihistamines and montelukast.
- 14 April 2022
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 183 (8) , 843-851
Serodominance Profile in a Dust Mite Complex Region
Background/Objective: The objective of this study was to describe the molecular sensitization profile of mite allergy in an area with a high environmental exposure of house dust mites (HDM) and storage mites. Methods: Skin prick tests were performed with standardized extracts (DIATER, Madrid, Spain). A specific commercial molecular panel (MADx) for Dermatophagoides pteronyssinus (Dpt), Dermatophagoides farinae (Dfar), Lepidoglyphus destructor (Ldt), Tyrophagus putrescentiae (Tput), and Blomia tropicalis (Blot) was correlated with clinical parameters in Galician (northwestern of Spain) HDM allergic patients. Results: Fifty patients (60% female) met the inclusion and exclusion criteria. All of the patient’s present rhinitis (50), 28% (14) rhinitis and asthma, and 18% (9) atopic dermatitis (AD). Hundred patients had a positive prick test for Dpt, followed by Dfar (92%), Ldt and Tput (74%), and Blot (68%). More than 50% recognized specific IgE for Der p 1, Der p 2, reaching 86% in the case of Der p 23. No statistically significant differences in IgE levels were found between patients with/without asthma and those with mild or moderate-severe rhinitis. Der p 7 was higher among rhinitis patients (p value 0.05). AD relative risk (RR) was increased in patients sensitized to Der f 2, Der p 2, and Der p 23. Der p 10 decreases the risk to have AD (RR 0.80). Conclusion: The evaluation of IgE results in a comprehensive panel of allergens allows differentiation of serological reactivity profiles with their clinical expression, to perform an optimal management. Improvements in component resolved diagnosis and more research on the clinical relevance of mite allergens are needed to achieve a genuine diagnosis leading to specific immunotherapy.
- 14 April 2022
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 183 (8) , 843-851
Serodominance Profile in a Dust Mite Complex Region
Background/Objective: The objective of this study was to describe the molecular sensitization profile of mite allergy in an area with a high environmental exposure of house dust mites (HDM) and storage mites. Methods: Skin prick tests were performed with standardized extracts (DIATER, Madrid, Spain). A specific commercial molecular panel (MADx) for Dermatophagoides pteronyssinus (Dpt), Dermatophagoides farinae (Dfar), Lepidoglyphus destructor (Ldt), Tyrophagus putrescentiae (Tput), and Blomia tropicalis (Blot) was correlated with clinical parameters in Galician (northwestern of Spain) HDM allergic patients. Results: Fifty patients (60% female) met the inclusion and exclusion criteria. All of the patient’s present rhinitis (50), 28% (14) rhinitis and asthma, and 18% (9) atopic dermatitis (AD). Hundred patients had a positive prick test for Dpt, followed by Dfar (92%), Ldt and Tput (74%), and Blot (68%). More than 50% recognized specific IgE for Der p 1, Der p 2, reaching 86% in the case of Der p 23. No statistically significant differences in IgE levels were found between patients with/without asthma and those with mild or moderate-severe rhinitis. Der p 7 was higher among rhinitis patients (p value 0.05). AD relative risk (RR) was increased in patients sensitized to Der f 2, Der p 2, and Der p 23. Der p 10 decreases the risk to have AD (RR 0.80). Conclusion: The evaluation of IgE results in a comprehensive panel of allergens allows differentiation of serological reactivity profiles with their clinical expression, to perform an optimal management. Improvements in component resolved diagnosis and more research on the clinical relevance of mite allergens are needed to achieve a genuine diagnosis leading to specific immunotherapy.
- 24 December 2020
- Published by Wiley in Contact Dermatitis
- Vol. 84 (6) , 464-466
Silver: An underdiagnosed allergen?
- 24 December 2020
- Published by Wiley in Contact Dermatitis
- Vol. 84 (6) , 464-466
Silver: An underdiagnosed allergen?